A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies (NCT05885555)

🧪 Interventions in This Study

• Ianalumab (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (24 Sites)

• Massachusetts General Hospital — Boston, Massachusetts
• Beth Israel Deaconess Med Center — Boston, Massachusetts
• Novartis Investigative Site — CABA,
• Novartis Investigative Site — Garran, Australian Capital Territory
• Novartis Investigative Site — Melbourne, Victoria
• Novartis Investigative Site — Wuhan, Hubei
• Novartis Investigative Site — Beijing,
• Novartis Investigative Site — Jinan,
• Novartis Investigative Site — Toulouse,
• Novartis Investigative Site — Dresden, Saxony
• Novartis Investigative Site — Jena, Thuringia
• Novartis Investigative Site — Giessen,
• Novartis Investigative Site — Torino, TO
• Novartis Investigative Site — Johor Bahru,
• Novartis Investigative Site — Katowice,
• Novartis Investigative Site — Seoul,
• Novartis Investigative Site — Barcelona, Catalonia
• Novartis Investigative Site — Aydin, Efeler
• Novartis Investigative Site — Istanbul, Fatih
• Novartis Investigative Site — Edirne, Merkez
• Novartis Investigative Site — Izmir,
• Novartis Investigative Site — Kocaeli,
• Novartis Investigative Site — Glasgow,
• Novartis Investigative Site — London,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Primary Immune Thrombocytopenia (ITP)

• Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) — Yuma, Arizona
• A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) — Fayetteville, Arkansas
• A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia — Phoenix, Arizona

Explore by condition: All Primary Immune Thrombocytopenia (ITP) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.